Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVXL-0255
- Development stage
- Preclinical
- Lead developer
- CleveXel Pharma
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
CVXL-0255 (also known as CPh-1012) is a small molecule, mixed and selective Type II kinase inhibitor targeting Spleen Tyrosine Kinase (SYK), Janus Kinase 3 (JAK3), and Tyrosine Kinase 2 (TYK2). Developed by CleveXel Pharma, it is designed to treat various immuno-inflammatory diseases by modulating multiple signaling pathways. The drug has demonstrated oral efficacy in canine models of atopic dermatitis and is being explored for human indications including atopic dermatitis, asthma (potentially via inhalation), and rheumatoid arthritis. As a Type II inhibitor, it is intended to offer a superior safety profile compared to traditional Type I inhibitors.
02
Targets
Beyond the preview
Go deeper on CVXL-0255.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVXL-0255.